PAR : ALCLS.PA

Cellectis S.A.

$2.514 EUR

-$0.04 (-1.41%)

Volume
100.45K
Average Volume
227.7K
Market Capitalization
$181.83M
P/E Ratio
-4.25
Dividend Yield
0.00%
Price Target
Year High
$4.84
Year Low
$2.03
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$1.52
Company Overview

PAR

Andre Choulika

Biotechnology

Healthcare

ALCLS.PA

229

FR

EUR

https://www.cellectis.com

33 1 81 69 16 00

F1775Q107

N/A

Liquidity Metrics

1.38

1.52

1.52

0.26

0.00

Sales & Valuation

$75.92M

3.04

4.81

-5.19

-0.40

Profitability

-$0.7

-$70.35M

-98.69%

-101.81%

-80.61%

-23.26%

P/E Metrics

-4.25

0.05

0.05

Analyst Price Target & Rating

Strong Sell

1/5

16 Analysts

%

Financial Health Scores

-1.37

2/9

$69.98M

$288.89M

$229.03M

-$64.56M

Key Metrics (TTM)

No key metrics data available.

Company Executives
Name Title
Pascalyne Wilson Director of Communications
Valerie Cros Principal Financial Officer & Principal Accounting Officer
Stephan Reynier Chief Regulatory & Pharmaceutical Compliance Officer
Kyung Nam-Wortman Executive Vice President & Chief Human Resources Officer
Marie-Bleuenn Terrier General Counsel & Secretary of the Board of Directors
Andre Choulika Co-Founder, Chief Executive Officer & Director
David J. Sourdive Co-Founder, Deputy Chief Executive Officer, Executive Vice President of CMC & Manufacturing and Director
Philippe Duchateau Chief Scientific Officer
Arthur Stril Chief Financial Officer & Chief Business Officer
Jean Charles Epinat Chief Technological Officer
Poll Results

No votes yet today — be the first to share your view!

About Cellectis S.A. (PAR:ALCLS.PA) Stock

Cellectis S.A., a clinical-stage biotechnology company founded in 1999 and headquartered in Paris, France, concentrates on immuno-oncology. The firm engineers therapeutic solutions utilizing gene-edited T-cells, which are modified to display chimeric antigen receptors (CARs) for the specific identification and destruction of cancer cells. Its operations are divided into two principal segments: Therapeutics and Plants. The company's pipeline features several allogeneic CAR T-cell product candidates. These include UCART19, aimed at CD19-expressing hematologic malignancies such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A, developed to treat relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316, targeting renal cell carcinoma; UCART123, for acute my ... eloid leukemia; and UCART22, addressing B-cell acute lymphoblastic leukemia. Additionally, Cellectis is advancing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. Cellectis has forged significant strategic partnerships and alliances with companies including Allogene Therapeutics, Inc., Les Laboratoires Servier, The University of Texas M.D. Anderson Cancer Center, and Iovance Biotherapeutics. It also maintains a strategic research and development collaboration with Cytovia Therapeutics, Inc.

Frequently Asked Questions

What is the current Cellectis S.A. (ALCLS.PA) stock price?

Cellectis S.A.(PAR:ALCLS.PA) stock price is $2.514 in the last trading session. During the trading session, ALCLS.PA stock reached the peak price of $4.84 while $2.03 was the lowest point it dropped to. The percentage change in ALCLS.PA stock occurred in the recent session was --1.41% while the dollar amount for the price change in ALCLS.PA stock was -$0.04.

ALCLS.PA's industry and sector of operation?

The PAR listed ALCLS.PA is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ALCLS.PA?

Pascalyne Wilson | Director of Communications
Valerie Cros | Principal Financial Officer & Principal Accounting Officer
Stephan Reynier | Chief Regulatory & Pharmaceutical Compliance Officer
Kyung Nam-Wortman | Executive Vice President & Chief Human Resources Officer
Marie-Bleuenn Terrier | General Counsel & Secretary of the Board of Directors

How many employees does ALCLS.PA have?

Number of ALCLS.PA employees currently stands at 229. ALCLS.PA operates from 8, rue de la Croix Jarry, Paris, IF 75013, FR.

Link for ALCLS.PA official website?

Official Website of ALCLS.PA is: https://www.cellectis.com

How do I contact ALCLS.PA?

ALCLS.PA could be contacted at phone #33 1 81 69 16 00 and can also be accessed through its website. ALCLS.PA operates from 8, rue de la Croix Jarry, Paris, IF 75013, FR.

How many shares of ALCLS.PA are traded daily?

The average number of ALCLS.PA shares traded daily for last 3 months was 227.7K.

What is the market cap of ALCLS.PA currently?

The market value of ALCLS.PA currently stands at $181.83M with its latest stock price at $2.514